Vor Biopharma (NASDAQ:VOR) Shares Up 12% – What’s Next?

Shares of Vor Biopharma Inc. (NASDAQ:VOR) rose 12% on Tuesday . The stock traded as high as $19.42 and last traded at $19.5360. 634,643 shares traded hands during trading, a decline of 42% from the average daily volume of 1,097,242 shares. The stock had previously closed at $17.45.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on VOR. Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Vor Biopharma in a report on Monday, May 18th. Wedbush boosted their target price on Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Weiss Ratings upgraded Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 30th. Finally, Wall Street Zen cut Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Vor Biopharma Stock Up 12.3%

The business’s fifty day moving average is $15.95 and its two-hundred day moving average is $15.06.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. Research analysts expect that Vor Biopharma Inc. will post -2.51 EPS for the current fiscal year.

Insider Transactions at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 165,150 shares of the business’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the completion of the transaction, the director directly owned 2,402,095 shares of the company’s stock, valued at approximately $37,881,038.15. The trade was a 6.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.27% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vor Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of VOR. China Universal Asset Management Co. Ltd. acquired a new position in shares of Vor Biopharma during the fourth quarter worth $36,000. Goldman Sachs Group Inc. raised its stake in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares in the last quarter. XTX Topco Ltd purchased a new stake in Vor Biopharma during the 2nd quarter worth about $66,000. Chung Wu Investment Group LLC purchased a new stake in Vor Biopharma during the 4th quarter worth about $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in shares of Vor Biopharma during the 4th quarter worth about $134,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).